BioBran is the main product of Daiwa Pharmaceutical Co., Ltd. (Setagaya-ku, Tokyo, Japan - President: Yasuo Ninomiya). Dr. M. Ghoneum (Professor of UCLA/Drew Medical College), one of the developers of BioBran, announced the latest research results at two academic presentations.

At the Federation of Clinical Immunology Society (FOCIS, San Francisco) in June, the doctor made a presentation entitled, “Effect of modified Arabinoxylan from rice bran (MGN-3/Biobran) on human neutrophils and monocyte functions in vitro.”

The outline is as follows:
The potential antibacterial and immunomodulatory effects of modified rice bran Arabinoxylan derivative (MGN-3/BioBran) on human phagocytic cells (monocytes and neutrophils) were investigated. Phagocytic cells in peripheral blood were incubated with Escherichia coli (E. coli) in the presence and absence of MGN-3.

MGN-3 enhanced phagocytosis of E. coli by the phagocytic cells in a dose-dependent manner, and was associated with the enhancement of oxidative bursts in neutrophils and monocytes. In the absence of bacteria, MGN-3 did not trigger oxidative bursts by phagocytic cells.

Also, incubation of 31 types of bacteria without phagocytic cells in the presence of MGN-3 did not affect bacterial growth, suggesting that MGN-3 does not have direct antibacterial activity, but rather acts to modulate phagocytic cell function. These findings may have applications in the treatment of infections in the elderly.

At the International Research Conference on Food and Cancer in Washington, D.C., Dr. Ghoneum spoke about “In vivo tumor inhibitory effects of Arabinoxylan rice bran (MGN-3/biobran) on Ehrlich Carcinoma-Bearing Mice.”

The summary of the presentation is as follows:
The study investigated in vivo antitumor activity of the modified rice bran Arabinoxylan compound (MGN-3/BioBran) against mice bearing Ehrlich Ascites Carcinoma (EAC) cells. The mice were inoculated in the right thigh and were intra-tumorally injected with MGN-3 after tumor growth.

MGN-3 treatment caused a significant delay of tumor growth compared to controls, and the following effects were confirmed:

(1) MGN-3 induces an apoptotic effect against EAC cells.
(2) Injection of mice with MGN-3 in the thigh caused a significant
　　increase in splenic NK activity as compared with controls.

These data may have clinical implications for the treatment of solid cancer.“BioBran” has obtained a process patent in nine countries, including Japan, the U.S., and Europe, establishing a position as an international product from Japan. The sales market has expanded and it is now sold in 38 countries.

・

Copyright(C)2006 Daiwa Pharmaceutical Co.,Ltd. All rights reserved. | HOME >